Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts. Founded in 2010, it focuses on the development of messenger RNA (mRNA) therapeutics, primarily vaccines.
Moderna is a leader in the field of mRNA technology, which uses messenger RNA to instruct cells to produce specific proteins. This technology has revolutionized vaccine development and holds potential for treating various diseases.
Beyond COVID-19, Moderna has a robust pipeline of mRNA vaccines and therapeutic candidates in development for various diseases, including influenza, HIV, respiratory syncytial virus, and cancer.
In 2023, Moderna achieved several notable milestones, including:
1. Receiving full approval for Spikevax from the U.S. Food and Drug Administration (FDA).
2. Initiating the first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against multiple respiratory viruses.
3. Agree with the Chinese government to develop mRNA drugs for exclusive use in China.
Moderna plays a vital role in the future of medicine and we are looking at adding the stock to our portfolio. Year to date, the stock is down about 49% and 2024 is looking to be a stable year for Moderna as long as it does not break and trade below support. This will pull the stock price back to its 2019 level.
Moderna is a leader in the field of mRNA technology, which uses messenger RNA to instruct cells to produce specific proteins. This technology has revolutionized vaccine development and holds potential for treating various diseases.
Beyond COVID-19, Moderna has a robust pipeline of mRNA vaccines and therapeutic candidates in development for various diseases, including influenza, HIV, respiratory syncytial virus, and cancer.
In 2023, Moderna achieved several notable milestones, including:
1. Receiving full approval for Spikevax from the U.S. Food and Drug Administration (FDA).
2. Initiating the first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against multiple respiratory viruses.
3. Agree with the Chinese government to develop mRNA drugs for exclusive use in China.
Moderna plays a vital role in the future of medicine and we are looking at adding the stock to our portfolio. Year to date, the stock is down about 49% and 2024 is looking to be a stable year for Moderna as long as it does not break and trade below support. This will pull the stock price back to its 2019 level.